BioLife Solutions (BLFS) Company Overview

BioLife Solutions (BLFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 million Unaudited revenue for FY2024 from Cell Processing of $73.5 million, exceeded the high end of previously raised guidance BOTHELL, Wash. , Jan. 13, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced 2024 fourth quarter and full year preliminary unaudited revenue from continuing operations.

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Troy Wichterman - Chief Financial Officer Rod de Greef - Chairman and Chief Executive Officer Garrie Richardson - Chief Revenue Officer Conference Call Participants Matt Stanton - Jefferies Brendan Smith - TD Cowen Anna Snopkowski - KeyBanc Matt Hewitt - Craig-Hallum Capital Group LLC Thomas Flaten - Lake Street Capital Markets Jade Montgomery - H.C. Wainwright & Co., LLC Operator Good afternoon, ladies and gentlemen, and thank you for standing by.

Cell Processing revenue grew 6%  sequentially to $19.0 million; 43% increase compared to 2023 GAAP gross margin of 51%  and non-GAAP adjusted gross margin of 54% GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20% Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million; total 2024 revenue guidance of $98.0 million to $100.0 million reflecting impact of SciSafe divestiture Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.

BOTHELL, Wash. , Oct. 31, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2024 financial results will be released after market close on Tuesday, November 12, 2024.

BioLife Solutions (BLFS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

BioLife Solutions, Inc. (NASDAQ:BLFS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Troy Wichterman – Chief Financial Officer Rod de Greef – Chairman and Chief Executive Officer Garrie Richardson – Chief Revenue Officer Conference Call Participants Jacob Johnson – Stephens Anna Snopkowski – KeyBanc Matt Stanton – Jefferies Steven Mah – TD Cowen Thomas Flaten – Lake Street Capital Markets Operator Good afternoon, and welcome to the BioLife Solutions Q2 2024 Shareholder and Analyst Conference Call. [Operator Instructions] Please note, this event is being recorded.

BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.23 per share a year ago.

Cell Processing revenue increased 11%  sequentially to $18.0 million GAAP gross margin of 51%  and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million or 17% Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million; Cell Processing revenue guidance increased to $70.0 million to $71.0 million Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.